Objective To compare the clinical effect in treating elderly lacunar infarction patients complicated with hyperlipidaemia and prehypertension between xuezhikang capsule and atorvastatin calcium tablets. Methods From June 2012 to March 2015 in the Department of Internal Medicine,Women's and Children's Hospital of Hubei Province,in the Department of Internal Medicine,Red Cross Hospital of Xinzhou District,Wuhan,a total of 124 elderly lacunar infarction patients complicated with hyperlipidaemia and prehypertension were selected,and they were divided into A group and B group,each of 62 cases. A total of 62 healthy old people admitted to the Women's and Children's Hospital of Hubei Province for physical examination were selected as control group. Patients of A group received xuezhikang capsule,while patients of B group received atorvastatin calcium tablets;both groups continuously treated for 8 weeks;patients of control group did not receive any treatment. SBP,DBP,serum levels of TG,TC,LDL-C,HDL-C,ApoA1,ApoB and hs-CRP before treatment were compared among the three groups;SBP, DBP,MAP,serum levels of TG,TC,LDL-C,HDL-C,ApoA1,ApoB,hs-CRP,GGT and CK before and after treatment were compared between A group and B group,and the incidence of adverse reactions of A group and B group was observed. Results SBP,DBP and serum levels of TG,TC,LDL-C,ApoB and hs-CRP of A group and B group were statistically significantly higher than those of control group,while serum levels of HDL-C and ApoA1 of A group and B group were statistically significantly lower than those of control group(P ﹤ 0. 05). No statistically significant differences of SBP,DBP,MAP,serum level of hs-CRP,GGT,CK,TG,TC,LDL-C,HDL-C,ApoA1 or ApoB was found between A group and B group before treatment(P ﹥ 0. 05);after treatment,SBP,DBP,MAP and serum levels of hs-CRP,GGT and CK of A group were statistically significantly lower than those of B group(P ﹤ 0. 05),while no statistically significant differences of serum level of TG,TC,LDL-C,HDL-C,ApoA1 or ApoB was found between A group and B group(P ﹥ 0. 05). No one of the two groups occurred any severe adverse reactions. Conclusion Xuezhikang capsule has similar lipid - regulating effect with atorvastatin calcium tablets,can more effectively reduce the blood pressure and risk of cerebrovascular disease, relive the vascular inflammatory reaction,and is safe.%目的：比较血脂康胶囊与阿托伐他汀钙片治疗老年腔隙性脑梗死（LI）伴高脂血症、高血压前期患者的临床疗效。方法选取2012年6月—2015年3月湖北省妇幼医院内科及武汉市新洲区红十字会医院内科收治的老年LI 伴高脂血症、高血压前期患者124例，按随机数字表法分为 A 组与 B 组，每组62例；另选取同期在湖北省妇幼医院进行体检的健康老年人62例作为空白对照组。A 组患者予以血脂康胶囊治疗，B 组患者予以阿托伐他汀钙片治疗，两组患者均连续治疗8周；空白对照组未予以任何治疗。比较治疗前3组受检者收缩压（SBP）、舒张压（DBP）、血脂指标〔三酰甘油（TG）、总胆固醇（TC）、低密度脂蛋白胆固醇（LDL-C）、高密度脂蛋白胆固醇（ HDL-C）、载脂蛋白 A1（ApoA1）、载脂蛋白 B（ApoB）〕及超敏 C 反应蛋白（hs-CRP）水平；治疗前后 A、B 组患者 SBP、DBP、平均动脉压（MAP）、血脂指标、hs-CRP水平、谷氨酰转肽酶（GGT）及肌酸激酶（CK）水平；A、B 组患者不良反应发生情况。结果 A、B 组患者 SBP、DBP 及血清 TG、TC、LDL-C、ApoB、hs-CRP水平高于空白对照组，血清 HDL-C、ApoA1水平低于空白对照组（P ﹤0.05）。治疗前 A、B 组患者 SBP、DBP、MAP 及血清hs-CRP、GGT、CK、TG、TC、LDL-C、HDL-C、ApoA1、ApoB 水平比较，差异无统计学意义（P ﹥0.05）；治疗后 A 组患者 SBP、DBP、MAP 及血清hs-CRP、GGT、CK 水平低于 B 组（P ﹤0.05），A、B 组患者血清 TG、TC、LDL-C、HDL-C、ApoA1、ApoB 水平比较，差异无统计学意义（P ﹥0.05）。A、B 组患者均未发生严重不良反应。结论血脂康胶囊与阿托伐他汀钙片对老年 LI伴高脂血症、高血压前期患者的调脂作用相当，血脂康胶囊可更有效地降低血压及脑血管疾病发生风险，减轻血管炎性反应，且不良反应少。
展开▼
